0001567619-19-018008.txt : 20190906
0001567619-19-018008.hdr.sgml : 20190906
20190906170557
ACCESSION NUMBER: 0001567619-19-018008
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190905
FILED AS OF DATE: 20190906
DATE AS OF CHANGE: 20190906
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ALSTODT LANCE
CENTRAL INDEX KEY: 0001756228
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37603
FILM NUMBER: 191080303
MAIL ADDRESS:
STREET 1: BIORESTORATIVE THERAPIES, INC.
STREET 2: 40 MARCUS DRIVE, SUITE 1
CITY: MELVILLE
STATE: NY
ZIP: 11747
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BioRestorative Therapies, Inc.
CENTRAL INDEX KEY: 0001505497
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
IRS NUMBER: 911835664
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 40 MARCUS DRIVE
CITY: MELVILLE
STATE: NY
ZIP: 11747
BUSINESS PHONE: (631) 760-8100
MAIL ADDRESS:
STREET 1: 40 MARCUS DRIVE
CITY: MELVILLE
STATE: NY
ZIP: 11747
FORMER COMPANY:
FORMER CONFORMED NAME: Stem Cell Assurance, Inc.
DATE OF NAME CHANGE: 20101110
4
1
doc1.xml
FORM 4
X0306
4
2019-09-05
0
0001505497
BioRestorative Therapies, Inc.
BRTX
0001756228
ALSTODT LANCE
C/O BIORESTORATIVE THERAPIES, INC.
40 MARCUS DRIVE, SUITE 1
MELVILLE
NY
11747
0
1
0
0
EVP and Chief Strategy Officer
Common Stock
2019-09-05
4
P
0
100
0.2549
A
20100
D
Common Stock
2019-09-05
4
P
0
9900
.2699
A
30000
D
Stock Option
.75
2028-10-15
Common Stock
500000
500000
D
The option vests to the extent of 100,000 shares as of October 15, 2018, 150,000 shares upon the earlier of October 15, 2019 or the date on which the initial patient recruitment for the Company's Phase II lumbar clinical trial occurs, and 250,000 shares as of October 15, 2020.
/s/ Lance Alstodt
2019-09-06